AmerisourceBergen, a leading pharmaceutical solutions organisation, has announced that it will change its name to ‘Cencora’ to better reflect its bold vision and purpose-driven approach to creating healthier futures.
Steven H. Collis, chairman, president & chief executive officer of AmerisourceBergen, said: “Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain.
"To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care.”
AmerisourceBergen intends to begin operating as Cencora in the second half 2023. The change to Cencora is aligned with the organisation’s growth strategy and continued emphasis on innovation. The multinational company has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.
Operating as Cencora, a unified and internationally inclusive name and brand, the company will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform of pharma and biopharma services to support pharmaceutical innovation and access.
